Mesenchymal Stromal Cell Therapy Shows Promise for Severe Bronchopulmonary Dysplasia in Extremely Preterm Infants

Can MSC Therapy Revolutionize Treatment for Severe BPD?

Mesenchymal stromal cell therapy offers promising results for extremely preterm infants with severe bronchopulmonary dysplasia, according to a recent clinical study conducted at Prof. Dr. Cemil Tascioglu City Hospital in Turkey. The study, which tracked outcomes in seven extremely preterm infants who received human umbilical cord-derived mesenchymal stromal cells (HUC-MSCs) after conventional therapies had been exhausted, demonstrated significant improvements not only in respiratory function but also in several comorbidities commonly associated with prematurity. This research provides valuable insights into the potential of repetitive MSC dosing as a late-term intervention for established severe bronchopulmonary dysplasia (sBPD), a condition that significantly impacts long-term outcomes in premature infants. The findings suggest that MSC therapy may offer a multifaceted approach to addressing the complex needs of these vulnerable patients, potentially extending benefits beyond the pulmonary system to other organs affected by premature birth complications.

The study population consisted of seven extremely preterm infants born between 23 weeks 6 days and 28 weeks of gestation, with birth weights ranging from 511 to 1131 grams. All infants had developed severe BPD despite conventional treatments and required significant respiratory support at the time of MSC therapy initiation. The treatment protocol involved administering HUC-MSCs via both intratracheal and intravenous routes, with each cycle consisting of 1×10^6 cells/kg delivered intratracheally followed by 0.5×10^6 cells/kg administered intravenously 30 minutes later. The first three infants received two treatment cycles separated by 15 days, one infant received three cycles at weekly intervals, and the remaining three infants underwent four weekly cycles. This approach allowed researchers to observe potential dose-response relationships and evaluate whether multiple cycles might enhance therapeutic efficacy in severe cases. Prior to MSC administration, six of the seven infants required invasive mechanical ventilation with fractional inspired oxygen (FiO2) levels ranging from 30% to 70%, highlighting the severity of their respiratory compromise.

Do the Results Demonstrate Both Pulmonary and Systemic Improvements?

The results demonstrated notable improvements in respiratory outcomes following MSC therapy. All seven infants achieved their primary respiratory goals, with six successfully transitioning from invasive to noninvasive ventilation between 21 and 38 days after initial treatment. Five of the seven infants were ultimately discharged breathing room air without supplemental oxygen support. Particularly encouraging was the observation that infants who received three or four treatment cycles appeared to demonstrate more robust improvements compared to those who received only two cycles, suggesting a potential dose-response relationship. One infant who received only two treatment cycles remained dependent on supplemental oxygen at discharge, while another could not be weaned from noninvasive ventilation and was transferred to the pediatric intensive care unit due to the parents' decision not to continue MSC treatment for financial reasons. These findings align with previous animal studies suggesting that multiple doses of MSCs may provide more substantial and sustained benefits in chronic lung disease models compared to single-dose regimens.

Beyond respiratory improvements, the researchers documented several secondary benefits that highlight the potential systemic effects of MSC therapy. In the first three infants, echocardiographic measurements revealed a 25-33% reduction in pulmonary arterial pressure within just one week of treatment initiation, suggesting rapid improvements in pulmonary vascular resistance. All seven infants demonstrated a decreased need for packed red blood cell transfusions following MSC therapy, with monthly transfusion rates declining from a pre-treatment range of 2.5-7.5 transfusions per month to 0.3-1.6 transfusions per month post-treatment. Similarly, the frequency of antibiotic courses decreased in all patients, potentially reflecting improved immune function or reduced susceptibility to infection. The researchers also observed regression of retinopathy of prematurity (ROP) in four infants and resolution or improvement of intraventricular hemorrhage (IVH) in four infants. These findings suggest that MSC therapy may offer benefits that extend well beyond its primary target organ, potentially addressing multiple comorbidities associated with extreme prematurity through mechanisms that remain to be fully elucidated.

What Are the Long-Term Outcomes and Challenges in MSC Therapy?

The long-term follow-up data, while preliminary, offer additional insights into the potential durability of MSC therapy effects. Four of the seven infants exhibited normal neurodevelopment at follow-up (ranging from 1 to 5 years of chronological age), while two were diagnosed with mild cerebral palsy. One infant passed away at 12 months of age due to sepsis. Several infants experienced recurrent respiratory infections requiring hospitalization during the follow-up period, suggesting that while MSC therapy may provide significant acute benefits, it may not completely prevent long-term respiratory vulnerability in this high-risk population. The researchers note that the immunomodulatory effects of MSCs appear to be temporary rather than permanent, which could explain the continued susceptibility to respiratory infections despite initial improvements in lung function. This observation underscores the complexity of addressing the multifaceted challenges associated with extreme prematurity and highlights the need for comprehensive, multidisciplinary approaches to long-term care for these vulnerable infants.

What Are the Mechanisms Behind MSC Therapy and Its Limitations?

The mechanisms underlying the observed benefits of MSC therapy in this study likely involve multiple pathways. MSCs are known to possess pro-angiogenic, anti-fibrotic, anti-inflammatory, antiapoptotic, antimicrobial, and immunomodulatory properties, all of which could contribute to improvements in BPD and associated comorbidities. The reduction in transfusion requirements observed in this study might be explained by MSC-mediated restoration of bone marrow function or enhanced erythropoietin production in the liver, as suggested by previous research. Similarly, the decreased frequency of septic episodes following MSC treatment aligns with known antimicrobial properties of these cells and their ability to enhance bacterial clearance, as demonstrated in animal models. The regression of ROP and IVH observed in some patients further supports the concept that MSCs may exert beneficial effects beyond the lungs, potentially through modulation of inflammatory pathways, enhancement of tissue repair mechanisms, or promotion of vascular stability.

Despite these promising results, the researchers acknowledge several limitations that must be considered when interpreting their findings. The study's small sample size, retrospective design, and lack of a control group make it difficult to establish definitive causal relationships between MSC therapy and observed outcomes. The natural history of severe BPD is variable, and some improvements might have occurred independent of MSC intervention. Additionally, while the dual-route administration approach (intratracheal plus intravenous) was hypothesized to enhance systemic distribution of MSCs, the actual biodistribution of these cells was not investigated due to ethical and practical constraints in this vulnerable patient population. These limitations highlight the need for larger, prospective, controlled trials to validate the findings and optimize treatment protocols for maximal efficacy and safety.

Which Unanswered Questions Could Guide Future MSC Research?

Looking ahead, this study raises several important questions for future research. How does the timing of MSC administration in relation to BPD onset affect outcomes? What is the optimal dosing schedule and route of administration? Are the observed systemic benefits directly related to MSC activity in target organs, or are they secondary to improvements in pulmonary function? Would combination approaches, incorporating MSCs with other therapeutic modalities, provide synergistic benefits? Addressing these questions will require rigorous clinical trials with appropriate controls, as well as mechanistic studies to elucidate the complex interactions between MSCs and host tissues in the context of neonatal pathophysiology. Could standardized protocols for MSC therapy in severe BPD eventually be developed and implemented across neonatal intensive care units worldwide, potentially transforming outcomes for this challenging patient population?

Is MSC Therapy Poised to Transform Neonatal Care?

In conclusion, this study provides valuable preliminary evidence supporting the potential benefits of late-term, repetitive HUC-MSC therapy for extremely preterm infants with established severe BPD. The observed improvements in respiratory function, combined with potential benefits for multiple comorbidities, suggest that MSC therapy may offer a comprehensive approach to addressing the complex needs of these vulnerable patients. While larger, controlled trials are needed to confirm these findings and optimize treatment protocols, this research represents an important step forward in the quest to improve outcomes for extremely preterm infants with severe BPD. As our understanding of MSC biology continues to advance, and as clinical experience with these cellular therapies grows, we may be approaching a new era in the management of neonatal respiratory diseases and their associated complications.

Summary

A clinical study from Turkey has investigated mesenchymal stromal cell (MSC) therapy in seven extremely preterm infants with severe bronchopulmonary dysplasia (BPD) who had not responded to conventional treatments. The infants, born between 23 and 28 weeks of gestation, received human umbilical cord-derived MSCs through both intratracheal and intravenous routes in multiple treatment cycles. All seven infants achieved their primary respiratory goals, with six successfully transitioning from invasive to noninvasive ventilation within 21 to 38 days after initial treatment, and five ultimately discharged breathing room air. Beyond respiratory improvements, the therapy demonstrated systemic benefits including 25-33% reduction in pulmonary arterial pressure within one week, decreased need for blood transfusions, reduced antibiotic requirements, and regression of retinopathy of prematurity and intraventricular hemorrhage in several patients. Infants receiving three or four treatment cycles showed more robust improvements compared to those receiving only two cycles, suggesting a dose-response relationship. Long-term follow-up revealed that four of seven infants exhibited normal neurodevelopment, while two developed mild cerebral palsy and one died from sepsis at 12 months. The therapeutic mechanisms likely involve multiple pathways including anti-inflammatory, pro-angiogenic, anti-fibrotic, and immunomodulatory properties of MSCs. Despite promising results, the study's limitations include small sample size, retrospective design, and lack of control group, highlighting the need for larger, prospective controlled trials to validate these findings and optimize treatment protocols for severe BPD in extremely preterm infants.